Check for updates

RESEARCH ARTICLE

REVISED Bacterial and fungal co-infections among ICU COVID-19 hospitalized patients in a Palestinian hospital: a retrospective cross-sectional study [version 2; peer review: 2 approved]

Hani A. Naseef [ID][1], Ula Mohammad[1], Nimeh Al-Shami [ID][1], Yousef Sahoury[1], Abdallah D. Abukhalil [ID][1], Mutaz Dreidi[2], Ibrahim Alsahouri[3], Mohammad Farraj[4]

[1]Pharmacy, Birzeit University, Ramallah, Palestine, 14, Palestinian Territory
[2]Department of Nursing, Birzeit University, Ramallah, Palestine, 14, Palestinian Territory
[3]Infectious Disease Department, Beit Jala Govermental Hospital, Ministry of Health, West Bank, Palestinian Territory
[4]Master Program in Clinical Laboratory Science, Birzeit University, Ramallah, Palestine, 14, Palestinian Territory

Abstract

Background: Diagnosis of co-infections with multiple pathogens among hospitalized coronavirus disease 2019 (COVID-19) patients can be jointly challenging and essential for appropriate treatment, shortening hospital stays and preventing antimicrobial resistance. This study proposes to investigate the burden of bacterial and fungal co-infections outcomes on COVID-19 patients. It is a single center cross-sectional study of hospitalized COVID-19 patients at Beit-Jala hospital in Palestine.

Methods: The study included 321 hospitalized patients admitted to the ICU between June 2020 and March 2021 aged ≥20 years, with a confirmed diagnosis of COVID-19 via reverse transcriptase-polymerase chain reaction assay conducted on a nasopharyngeal swab. The patient's information was gathered using graded data forms from electronic medical reports.

Results: The diagnosis of bacterial and fungal infection was proved through the patient's clinical presentation and positive blood or sputum culture results. All cases had received empirical antimicrobial therapy before the intensive care unit (ICU) admission, and different regimens during the ICU stay. The rate of bacterial co-infection was 51.1%, mainly from gram-negative isolates (*Enterobacter* species and *K.pneumoniae*). The rate of fungal co-infection caused by *A.fumigatus* was 48.9%, and the mortality rate was 8.1%. However, it is unclear if it had been attributed to SARS-CoV-2 or coincidental.

Conclusions: Bacterial and fungal co-infection is common among COVID-19 patients at the ICU in Palestine, but it is not obvious if these cases are attributed to SARS-CoV-2 or coincidental, because little data is available to compare it with the rates of secondary infection in local ICU departments before the pandemic. Comprehensively, those

Open Peer Review

Approval Status ✔✔

	1	2
version 2 (revision) 30 May 2022	✔ view	✔ view
version 1 11 Jan 2022	? view	? view

1. **Maher Khdour** [ID], Al-Quds University, Abu Dis, Palestinian Territory

2. **Hamza Maswade**, Qassim University, Buraydah, Saudi Arabia

Any reports and responses or comments on the article can be found at the end of the article.

conclusions present data supporting a conservative antibiotic administration for severely unwell COVID-19 infected patients. Our examination regarding the impacts of employing antifungals to manage COVID-19 patients can work as a successful reference for future COVID-19 therapy.

Keywords
COVID 19, Co-infection, Palestine, Iron supplements, ICU

This article is included in the Emerging Diseases and Outbreaks gateway.

Corresponding author: Hani A. Naseef (hshtaya@birzeit.edu)

Author roles: Naseef HA: Project Administration, Supervision, Writing – Review & Editing; **Mohammad U**: Data Curation, Formal Analysis, Writing – Original Draft Preparation; **Al-Shami N**: Formal Analysis, Writing – Original Draft Preparation; **Sahoury Y**: Data Curation, Formal Analysis, Writing – Original Draft Preparation; **Abukhalil AD**: Methodology, Writing – Review & Editing; **Dreidi M**: Methodology, Writing – Review & Editing; **Alsahouri I**: Data Curation; **Farraj M**: Writing – Review & Editing

> **REVISED** **Amendments from Version 1**
>
> After carefully considering the reviewers' valuable comments, we have made changes in the new version accordingly. Following are the significant differences:
>
> 1- Patients classification according to the number of chronic diseases for each patient (Table 2).
> 2- Data concerning coronary heart disease and cancer added to Table 2.
> 3- Clarification concerning the test done for the patients upon hospital admission (on the abstract).
> 4- A significant association was found between the residency duration and SpO$_2$ (*P*=0.032). The results revealed a significant association between ICU residency duration and the empirical antibiotics (*P*<0.001) (Added to the results).
> 5- The mortality rate of 8.1% (26) for patients admitted to the ICU due to Covid-19 coinfections found by this study is much lower than other reported rates of 25.7% in a systematic review that included 15 studies in different countries (Added to the discussion).
>
> **Any further responses from the reviewers can be found at the end of the article**

Introduction

Severe Acute Respiratory Syndrome Coronavirus 2 (SAR-CoV-2) is a highly contagious novel viral pathogen that provokes an immediate spread among hospitalized patients with Community-Acquired Pneumonia (CAP)[1]; extending from mild symptoms in approximately 84% of patients to life-threatening hypoxic conditions necessitating admittance into the Intensive Care Unit (ICU) and oxygen support.[2] Additionally, it causes multi-organ failure that involves sepsis and thromboembolic complications, which progresses into an acute kidney and cardiac injury.[3] On March 11th, 2020, the World Health Organization (WHO) deemed coronavirus disease 2019 (COVID-19) a pandemic disease due to its unusual transmission speed and the wide scale of infection.[4]

The bacterial and fungal co-infections are frequently recurring due to respiratory viral diseases. For example, most deaths in the Spanish flu pandemic in 1918 were due to subsequent bacterial infection.[5] The possibility of co-infections raises concerns as it hinders COVID-19 management, worsens prognosis, and might increase the fatality rate. The reported prevalence of bacterial co-infection varies between studies. Previous studies showed a low prevalence of early bacterial coinfection.[6,7] On the other hand, data from France pointed to a high prevalence of early bacterial coinfection during severe COVID-19 pneumonia.[8]

Throughout the pandemic, evaluation of gathered specimens from hospitalized COVID-19 patients reported the following as the most prevalent organisms that induce co-bacterial infection: *S. aureus, S. epidermidis, H. influenzae, Streptococcus* spp., *E. coli, K. pneumoniae,* and *P. aeruginosa*.[9] Therefore, many COVID-19 treatment protocols include empirical antibiotic therapy to cover suspected organisms. Thirty studies were summarized in a systematic review, including 3834 COVID-19 patients. Overall, only 7% of the hospitalized patients were confirmed to have bacterial co-infection with one or more pathogens, primarily in seriously ill patients.[10] On the contrary, diagnosis and/or treatment of fungus infections in COVID-19 patients are neglected or delayed, and the actual prevalence of fungal co-infection is yet to be established. Few studies addressed this issue; one systematic review meta-analysis research was carried out in China on 2780 confirmed SAR-CoV-2 participants from nine relevant articles. After fungal culturing at admission, 0.12%-0.15% of the cases were positive for fungal infection, and Asian patients were more likely to acquire fungal co-infection than the patients in the studies from the U.K. The infecting fungi include *Aspergillus, Candida, Cryptococcus neoformans,* and *Pneumocystis*.[11]

The exact mechanism of microbial co-infection is inadequately understood. Virologists assumed that the viruses attach and penetrate the host's airway epithelial cells creating an inflammatory response, desensitizing Toll-like receptors, and leading to cellular apoptosis in numerous mechanisms.[12] In addition, it debilitates the body's defense and induces cellular dysfunction and death.[12]

Viruses aid in proliferation, colonization, and invasive infection of opportunistic nosocomial pathogens or normal respiratory tract flora, hindering the innate immune response, compressing airway mucus, and disrupting the cilia allowing the virus to spread and adhere to more sites.[3] Furthermore, various researchers[13,14] highlighted the synergy regulations among viruses and bacteria; both are jointly advantageous, aggravating clinical outcomes. If this cooperation is confirmed, the management of some viral infections with antibiotics becomes further necessary.[15]

COVID-19 has been chiefly linked to high levels of inflammatory markers, such as elevated levels of C-reactive protein and procalcitonin. Accordingly, the similarity between Sar-CoV-2 and bacterial infections in radiological infiltrates and laboratory findings makes it challenging to provide a precise diagnosis in daily medical practice.[16] However, according to

current studies, most COVID-19 patients did not have bacterial or fungal co-infections upon admission or through the hospital stay, even though they received antibiotics upon admission or before diagnosis.[17] Furthermore, many factors advocated escalation of antimicrobial consumption during the pandemic: lack of specific antiviral agents, the overload of the health services' capacities, saturated laboratories, and diagnosis uncertainty.[18] As a result, clinicians are obliged to prescribe broad-spectrum multi-antibiotic regimens to treat all the possible infected pathogens.[19] Therefore, this study aimed to investigate and evaluate bacterial and fungal co-infection burden and prevalence among COVID-19 patients admitted to a treatment facility at Beit-Jala hospital in Palestine. In addition, it reveals the etiology of the infection, provides the antimicrobial stewardship that was used in the hospital and provides insight into the association of clinical outcomes with several factors and comorbidities.

Methods

Ethics and consent

The current research is based on data extraction from electronic medical reports, and as such, it is not considered human subject research. Neither patients nor the public was involved in this research's design, conduct, or reporting. The research was done retrospectively and without patient involvement. The study was approved by the Scientific Research Ethics Committee of Birzeit University on 27-2-2021 and by Beit-Jala hospital on 10-3-2021. The permission to use the generated data was obtained from the Beit Jala Governmental Hospital laboratory administration.

Study design and study population

This single-center cross-sectional study was conducted at Beit-Jala hospital, one of the central institutes for treating SAR-CoV-2 patients in Palestine. Patients included in this study were aged 20 years and older as patients under 20 are not admitted to this hospital. The records were for critically ill patients admitted to the ICU between June 2020 and March 2021. All patients were diagnosed with COVID-19 via reverse transcriptase-polymerase chain reaction assay (RT-PCR) conducted on nasopharyngeal swab specimens. A total of 458 records of moderate-severe COVID-19 ill patients were screened and evaluated. 321 patients who had positive cultures for bacteria or fungi within 48 hours of hospital admission were included in the study, and patients with negative cultures were excluded.

Data extraction and analysis

Data extraction was done manually by one researcher between the 15th-29th of March 2021 and verified by a second researcher, using graded data forms from electronic medical reports. The obtained data were socio-demographics, chronic comorbidities, laboratory findings (CRP, leukocytes, blood oxygen saturation), duration of the ICU stay, and if they had taken an iron supplement. The bacterial or fungal co-infection was proved through clinical presentation and positive blood or sputum testing via Laboratory Information System. Before and during the ICU admission, antimicrobial utilization was recorded, and the reports were double-checked for accuracy and completeness.

Data were analyzed, socio-demographic and clinical characteristics were summarized using relevant descriptive statistics, and categorical variables as percentages and frequencies. Pearson's Chi-square test was performed to determine the association between the main parameters: the ICU residency duration and the other factors such as age, gender, iron supplements, antibiotics administration before and during the ICU admission, smoking habits, and comorbidities. Data was analyzed and presented using SPSS version 22.0.

Definitions

Co-infection is a sequela that occurs during or after the primary causative pathogen or treatment. The isolated bacteria or fungi obtained from COVID-19 patients should be clinically relevant, not microbiota or contaminants. All the microbiological samplings were conducted upon the hospital's entry and before the ICU admittance, and only patients holding positive bacterial or fungal outcomes were admitted into the unit. In combination with decision-making, a scope of tests should be met to provide permission on who necessitates access, including computerized tomography (CT) scans to reveal ground-glass opacification, which correlated with pneumonia. In addition, supplementary laboratory outcomes were crucial in making the diagnosis, such as C-reactive protein (CRP) level, Oxygen saturation (SpO$_2$), Leukocyte numbers, and body temperature. Patients were immediately admitted to the ICU if two or more of the above matched positive isolates test and their CT scan showed pneumonia.

Patient status was evaluated based on laboratory findings. For example, CRP values ranged between 4.5-8.5 mg/dL and were rated as moderate and ≥8.5 mg/dL as severe. Leukocytes results in the 4.6-8 g/L range were considered mild, while >8 g/L indicated seriously ill patients. Normal oxygen saturation was considered ≥95%, but in COVID-19 patients, an oximeter reading at the rest of 90% or lower was classed as a severe case. The body temperature was deemed high if it was between 38-39 °C and very high if it was >39 °C.

Results
Presenting demographics
A total of 458 moderate-severe ill patients were screened and evaluated, and of those, 321 participants were included in this study. The patient's demographics and clinical characteristics are presented in Table 1. Overall, 48.9% (170) were

Table 1. Demographics, medical history and antibiotic regimens. (N 321; ICU: intensive care unit; SpO$_2$: oxygen saturation).

Gender	Male		162 (50.5%)
	Female		159 (49.5%)
Age (years)	20-40		54 (16.8%)
	41-64		157 (48.9%)
	>65		110 (34.3%)
Smoking habits	Yes		133 (41.4%)
	No		188 (58.6%)
Presence of comorbidities	Diabetes mellitus		250 (77.9%)
	Atrial hypertension		213 (66.4%)
	Obesity		118 (36.8%)
	Coronary heart disease		74 (23.1%)
	Cancer		66 (20.6%)
	No personal history		13 (4%)
Laboratory findings on day of ICU admission	CRP	Moderate	175 (54.5%)
		High	146 (45.5%)
	Leukocytes	Moderate	79 (24.6%)
		High	242 (75.4%)
	SpO$_2$	>90%	71 (22.1%)
		<90%	250 (77.9%)
	Fever	High	94 (29.3%)
		Very high	227 (70.7%)
Microbiological findings	*A. fumigatus*		157 (48.9%)
	Enterobacter		80 (24.9%)
	K. pneumoniae		54 (16.8%)
	P. aeruginosa		10 (3.1%)
	vancomycin-resistant enterococci		10 (3.1%)
	S. aureus		9 (2.8%)
	Invalid data		1 (0.3%)
Antibiotic regimen before admittance into the ICU	Ceftriaxone (2 g/day)		223 (69.5%)
	Ampicillin/sulbactam (12 g/day)		98 (30.5%)
Antibiotic regimen during the ICU stay	Meropenem+ vancomycin (2 g + 1 g/day)		138 (43.0%)
	Piperacillin/tazobactam + Levofloxacin (13.5 g+ 500 mg/day)		114 (35.5%)
	Fluconazole (200 mg/day)		69 (21.5%)
Iron supplement [376 mg] administration	Yes		201 (62.6%)
	No		120 (37.4%)
Duration of ICU stay (days)	1-6		234 (72.9%)
	7-11		61 (19.0%)
	Death		26 (8.1%)

41-64 years of age, and 50.5% (162) were males. Prevailing chronic medical conditions included diabetes mellitus at 77.9% (250), atrial hypertension at 66.4% (213), obesity at 36.8% (118), cancer at 20.6% (66), and coronary heart disease at 23.1% (74). 4% (13) of patients did not have a past medical history or comorbidity. 58.6% (188) were not smokers, and 62.6% (201) were supplemented with Iron 376 mg/day intravenously for three days. Additionally, all the participants in this study had received N-acetyl-cystine at 1200 mg/day, which began when they were admitted and continued until they left.

Bacterial and fungal co-infection

The overall mortality rate in this study was (26/321*100% = 8.1% (26)), while 72.9% (234) of the patients remained in the ICU for 1-6 days. Each patient was infected with one type of bacteria or fungi, which presented as a respiratory infection, bacteremia, and skin infections. A total of six different pathogens were detected in the samplings and considered the infecting organisms. The most abundant types were *Aspergillus fumigatus* 48.9% (157) and *Enterobacter* 24.9% (80), as shown in Table 1.

Table 2. Impact of different non-significant values on the duration in the ICU. (N 321; ICU: intensive care unit; SpO_2: oxygen saturation).

Parameter		Duration 1-6 days	Duration 7-11 days	Death	*P* value
Age (years)	**20-40**	41 (75.9%)*	10 (18.5%)	3 (5.6%)	0.413
	41-64	119 (75.8%)	28 (17.8%)	10 (6.4%)	
	>65	74 (67.3%)	23 (20.9%)	13 (11.8%)	
Diabetes	**Yes**	180 (72.0%)	49 (19.6%)	21 (8.4%)	0.794
	No	54 (76.1%)	12 (16.9%)	5 (7.0%)	
Hypertension	**Yes**	156 (73.2%)	43 (20.2%)	14 (6.6%)	0.317
	No	78 (72.2%)	18 (16.7%)	12 (11.1%)	
Obesity	**Yes**	81 (68.6%)	25 (21.2%)	12 (10.2%)	0.383
	No	153 (75.4%)	36 (17.7%)	14 (6.9%)	
Coronary heart disease	**Yes**	53 (71.6%)	13 (17.6%)	8 (10.8%)	0.607
	No	181 (73.3%)	48 (19.4%)	18 (7.3%)	
Cancer	**Yes**	44 (66.7%)	12 (18.2%)	10 (15.2%)	0.062
	No	190 (74.5%)	49 (19.2%)	16 (6.3%)	
No personal history of chronic diseases	**Yes**	10 (76.9%)	0 (0%)	3 (23.1%)	0.035
	No	224 (72.7%)	61 (19.8%)	23 (7.5%)	
Number of chronic disease (n = 308)	**One**	43 (811%)	7 (13.2%)	3 (5.7%)	0.065
	Two	90 (71.4%)	31 (24.6%)	5 (4%)	
	More than two	91 (70.5%)	23 (17.8%)	15 (11.6%)	
Smoking	**Yes**	103 (77.4%)	25 (18.8%)	5 (3.8%)	0.052
	No	131 (69.7%)	36 (19.1%)	21 (11.2%)	
CRP	**Moderate**	128 (73.1%)	33 (18.9%)	14 (8.0%)	0.994
	High	106 (72.6%)	28 (19.2%)	12 (8.2%)	
Leukocytosis	**Moderate**	59 (74.7%)	18 (22.8%)	2 (2.5%)	0.089
	High	175 (72.3%)	43 (17.8%)	24 (9.9%)	
SpO_2	**<90**	188 (75.2%)	40 (16.0%)	22 (8.8%)	0.032
	>90	46 (64.8%)	21 (29.6%)	4 (5.6%)	
Fever	**High**	71 (75.5%)	19 20.2%)	4 (4.3%)	0.265
	Very high	163 (71.8%)	42 (18.5%)	22 (9.7%)	

*The percentages indicate proportion of patients within each category in any duration. Chi-square test was used; C-reactive protein (CRP), Oxygen saturation (SpO_2).

Table 3. Impact of different significant values on the duration in the ICU (intensive care unit).

Parameter		Duration 1-6 days	Duration 7-11 days	Death	*P*
Ampicillin/sulbactam		52 (53.1%) **	29 (29.6%)	17 (17.3%)	<0.001
Ceftriaxone		182 (81.6%)	32 (14.3%)	9 (4.0%)	
Piperacillin/tazobactam+levofloxacin		57 (50.0%)	37 (32.5%)	20 (17.5%)	<0.001
Meropenem+vancomycin		108 (78.3%)	24 (39.3%)	6 (4.3%)	
Fluconazole		69 (100%)	0 (0%)	0 (0%)	
Iron Supplement	Yes	199 (99%)	0 (0%)	2 (1.0%)	<0.001
	No	35 (29.2%)	61 (50.8%)	24 (20.0%)	
Fungi		126 (80.3%)	24 (15.3%)	7 (4.5%)	0.008
Bacteria		108 (65.9%)	37 (22.6%)	19 (11.6%)	

**The percentages indicate proportion of patients within each category in any duration. Chi-square test was used.

Patterns of antibiotic use

In terms of antibiotic prescription patterns, through the first 24 hours of hospital admission and based on per case specificity, the proper liver or kidney function tests were conducted in all cases to determine the appropriate regimen for treating bacterial or fungal infections. Before ICU admission, the treatment duration was six days on an average; 69.5% (223) received ceftriaxone 2 g/day, and 30.5% (98) patients had received ampicillin and sulbactam 12 g/day; both regimens were administered intravenously (IV). Upon ICU admission, every patient received at least one IV antibiotic regimen throughout their ICU stay. 43.0% (138) received combination of meropenem 2 g/day, and vancomycin 1 g/day, and 35.5% (114) were given piperacillin/tazobactam 13.5 g/day and levofloxacin 500 mg/day. By January and after getting financial support from the Ministry of Health, patients infected with *A. fumigatus* started therapy with fluconazole 200 mg/day. Since then, 100% of the patients with fungal infections have been successfully treated. Considering different regimens had notable distinct outcomes, analysis was performed to determine the association linking antimicrobial therapy class and the ICU stay or death (Table 2). After hospital discharge, patients taking IV antibacterial medications were switched to oral azithromycin. Patients treated with Fluconazole IV switched to oral Fluconazole 150 mg/week for two days of treatment.

Table 2 reports no significant association between the ICU stay duration with age, laboratory test results, or having a chronic disease. However, a significant association was found between the residency duration and having a personal history with no chronic diseases (*P*=0.035): (3; 23.1%) of patients with no chronic diseases have died after being admitted to ICU compared to (23; 7.5%) of patients diagnosed with at least one chronic disease. Add that a significant association was found between the residency duration and SpO$_2$ (*P*=0.032): patients whose SpO$_2$ levels were <90% (188; 75.2%) were admitted in the ICU for a shorter duration (1-6 days) compared to patients whose SpO$_2$ read >90% (46; 64.8%).

Table 3 shows a significant association between the ICU residency duration and the infecting isolates (*P*=0.008). The patients suffering from fungal co-infection (126; 80.3%) spent fewer days in the ICU than patients with bacterial co-infection (108; 65.9%).

The selection of empirical antimicrobial options was associated with the length of hospital stay. There was a significant association between ICU residency duration and the empirical antibiotics (*P*<0.001). Patients administered ceftriaxone (182; 81.6% of the patients given ceftriaxone) were more likely to stay in the ICU for fewer days than patients administered ampicillin/sulbactam (52; 53.1%). In addition, patients who received fluconazole (69; 100%) significantly stayed for fewer days in the ICU compared to those administered piperacillin and tazobactam with levofloxacin (57; 50%) or meropenem with vancomycin (108; 78.3%) respectively (*P*<0.001).

Moreover, patients that were administered iron supplements as part of their therapy regimen (199; 99%) were significantly more likely to stay for a shorter duration of time compared with those who were not administered iron (35; 29.2%, *P*<0.001).

Discussion

In this research, the characteristics of co-infection in 321 severely ill COVID-19 patients were evaluated. The mortality rate of 8.1% (26) for patients admitted to the ICU due to Covid-19 coinfections found by this study is much lower than other reported rates of 25.7 % in a systematic review that included 15 studies in different countries.[20] Despite the absence

of antimicrobial stewardship in urgent response, the hospital's initiation of drastic empirical administration was crucial for preventing or treating suspected infections. In addition, the hospital's guideline adherence to empiric antimicrobial therapy and the other drugs was adequate. Furthermore, many factors could affect this finding, including the age and living situations; in our sample, two-thirds of participants were less than 65 years old. In addition, all participants did not live in nursing homes or elderly homes where a higher rate of antimicrobial resistance is expected.

COVID-19 patients are at risk of fungal infections during the latter stages of the disease due to seriously damaged alveoli and the decline in leukocyte counts.[21] Based on the knowledge of SARS in 2003 and the invasive Aspergillosis, it is vital to consider the possibility of a life-threatening fungal infection accompanying COVID-19. At the beginning of blood/sputum culturing, the number of cases infected by *A. fumigatus* was 48.9% (157). Those patients were initially given antibacterial regimens before and during their ICU stay without fluconazole due to medication cost. Fluconazole was added to the hospital formulary by January and confirmed fungal infections were treated with fluconazole. The addition of fluconazole to empirical therapy had reduced the average ICU stay from six days to less than two days, and the mortality rate from *A. fumigatus* decreased from 4.5% to 0%. Infection disease specialists realized the risk of fungal co-infection through the pandemic; the French High Council for Public Health recommended that clinicians concentrate on fungal infections in COVID patients, particularly in severe disease cases.[21]

Bacterial co-infection was recorded in 51.1% (164) of cases, with higher mortality rates among *Enterobacter* infected patients; this may be due to its known drug resistance. It should be noted that normal oral flora colonization or contamination may occur, particularly in the sputum specimens. In general, the empirical treatment with ceftriaxone or ampicillin/sulbactam showed minimal benefits to the clinical status. However, we observed a better prognosis with ceftriaxone than ampicillin/sulbactam, with mortality rates at 4% (9) and 17.3% (17), respectively; more studies are needed to confirm this association.

The wide-spectrum antimicrobial regimens are administered once the bacterial co-infection is confirmed and the patient is admitted into the ICU. Unfortunately, there is no available data to compare COVID-19 patients who received antibacterial agents with those who did not, which could help determine therapeutic efficacy. However, a regimen of piperacillin with tazobactam and levofloxacin resembles meropenem and vancomycin in terms of clinical outcomes and management rate. Other studies had revealed a higher rate of mortality and organ failure in patients administered meropenem.[17] Furthermore, after the recovery and discharge from the hospital, all outpatients were prescribed azithromycin, which also has antiviral activity and may decrease the incidence of acute organ failure.[17]

Earlier examinations illustrated that multiple antibiotic administrations did not alter the disease progression or patients' higher mortality rates.[22] In our study, it appeared to induce a good prognosis. Ceftriaxone, meropenem, and vancomycin regimens have been linked with more favorable outcomes and lower mortality rates. Until solid evidence is available, antimicrobials should be maintained for critical cases and constantly re-evaluated based on the patient's progress. The antimicrobial therapy must only cover the suspected or confirmed bacterial infection.

Antibiotic resistance and allergic reactions are multifactorial issues, and the pandemic has impacted the health system and provided a suitable environment for bacteria to become resistant to antimicrobials. In our study, all COVID-19 patients were admitted to the ICU and received at least four diverse types of broad-spectrum antibacterial agents; in addition, the accessibility of over-the-counter antimicrobials had undeniably grown through the pandemic.[19] This inappropriate behavior will lead to the evolution of high levels of antibiotic-resistant bacteria.

This study's unusual incidence of bacterial or fungal infections and mortality rates differs from other published studies.[11,23] This significant finding is due to the characteristics of critically ill patients receiving therapy via invasive catheters and being at risk of infection by nosocomial pathogens. Moreover, the unusual rate of infection has been credited to the exhaustion in the clinical care system, creating a prolonged hospital exposure, principally in the major waves of the virus.

Patients included in this study were 100% severe-critical ill. Therefore, it is necessary to differentiate between mild-moderate and severe patients and prioritize the ICU admittance. Fever was the notable symptom of SARS-CoV-2 infection identified at the early stages of the disease. Regarding laboratory findings, leukocytosis occurred in critically ill patients with distinct grades, and it was observed in 11.4% of severe COVID-19 cases.[24] Leukocytosis aids in the disease progress evaluation and reflects the severity of COVID-19 infection; it is exacerbated by the cytokine storm and inflammatory mediators that drive apoptosis and pulmonary microvascular destruction, creating alveolar oedema. The increased level of CRP is a diagnostic biomarker for coronavirus in distinguishing moderate and critical patients. The pathogenesis of COVID-19 involves a vigorous inflammatory response that manages a dysregulated flood of immune

cells and signaling molecules.[25] In general, viral respiratory infections have been linked to hypoxia. COVID-19 patients are considered hypoxic if their oxygen saturation level is <90%, while the normal SpO_2 is ≥95% at rest in healthy people. Hypoxia is a fearful condition that is monitored and adjusted by mechanical ventilation.[26] Although several studies[27,28] reported links between laboratory findings and clinical outcomes, our cases did not show a significant link.

Throughout the coronavirus pandemic, tobacco smoking issues and the risk of infection was constantly reviewed. Published research[29] indicated that smokers are twice as likely to develop severe COVID-19 as nonsmokers, as smoking tobacco induces alterations in the respiratory tract and cell-mediated immune response.[29] Furthermore, current smokers have higher ACE-2 gene expression than non-smokers; this gene is responsible for ACE-2 receptors production, which COVID-19 attaches to and penetrates the cells, thus raising the chance of infection.[30] Our study did not find an association between smoking habits and the duration of ICU stay or clinical prognosis.

Numerous investigations[31,32] found that older COVID-19 patients aged ≥50 years were correlated with a higher risk for severe signs, atypical presentation, the opportunity for co-infections, and higher fatality rates than patients <50 years of age. The rate usually increases rapidly with age, which is not surprising due to the drop in natural immunity with aging and associated comorbidities. In addition, it is believed that older people are prone to adverse drug reactions.[32] In general, people of older ages are more prone to becoming infected with the COVID virus than younger people.[32] A review reported that the fatality rate is doubled in males compared to females; it stated that male patients might have higher ACE-2 enzyme activity, directed by male sex hormones, contributing to more risk factors for SARS-CoV-2 infection worsening clinical outcomes.[33] Additionally, the smoking rate is higher in males.[33]

Effects of comorbidities such as hypertension, diabetes mellitus, coronary heart disease, and cancer were compared between survivors and non-survivors of COVID-19. Participants with comorbid conditions have a significantly greater fatality rate than those without them because they have decreased natural immunity and are poly-pharmacy patients.[34,35] There was no association between age, gender, or comorbidities with the clinical outcomes and ICU stay duration in our study.

Previous reports described mild anemia in COVID-19 patients at the ICU; due to severe inflammation that consumes iron,[36] the innate immune system limits the bioavailability of iron in order to diminish viral replication and infection. Accordingly, iron absorption from the diet is reduced, and the liver generates hepcidin, which blocks iron from carrying out of the cell. Accordingly, iron supplementation may exacerbate the disease and increase the inflammatory process.[37] However, no solid investigations were performed on the relation between iron and clinical results in COVID-19 patients. In the study, 62.6% of the patients received IV iron supplements for three days based on a randomized clinical trial. 99% had improved and stayed for a shorter time (1-6 days) in the ICU than those who did not receive IV iron; thus, it can be suggested that the iron provided an enhancement to immunity. Therefore, there is a strong association between low serum levels of iron and an increased infection rate and morbidity.

COVID-19 produces oxidative stress irregularity, and this process has been enhanced by glutathione reduction. Thiones are synthesized in a multi-step process involving N-acetyl-cysteine (NAC). Thiones are also ACE-2 blockers, thereby diminishing SARS-CoV-2 penetration into the cell. In a placebo-controlled study, NAC administration had reduced plasma inflammatory biomarker levels via several mechanisms. Besides antioxidant activity, NAC has vasodilator activity, especially in the intravenous route. In addition, it has mucolytic properties, inhibits RNA virus replication, and has confirmed protective effects against comorbid conditions, including cardiovascular diseases.[38] In our study, patients received NAC 1200 mg/day during the hospital stay, and even after discharge, they showed a good prognosis and improvement in their health status.

Strengths and limitations of this study
This is the first research addressing co-infection among COVID-19 patients in Palestine and offering clinical base recommendations for patient management. Our study shows a high prevalence of fungus and bacterial co-infection among COVID-19 patients admitted to the ICU, which requires appropriate management and attention. The study findings support the importance of assessing fungus co-infection in COVID-19 patients, and the early initiation of an antifungal agent will decrease morbidity and mortality. Our examination of the impacts of employing antifungals to manage COVID-19 patients can be a successful reference for future COVID-19 therapy.

This research has some limitations: first, it is a retrospective cross-sectional study holding obstacles restricting the potential bias and difficulty proofing the relation between the exposure and the outcome. Additionally, it is a single-center study, and its results could vary in another setting. Nevertheless, these conclusions present data supporting a conservative antibiotic administration for severely unwell COVID-19 infected patients.

Conclusion

The COVID-19 pandemic exerts pressure on healthcare professionals, including a high probability of infection. It is eminent to save lives during this pressure, even if it means multi-drug antimicrobial regimens for prevention or treatment. However, the insufficiency of data about antibiotic types, dosage, and duration of treatment through the pandemic continues to be challenging to health care providers. In addition, bacterial and fungal co-infection is common among COVID-19 patients at the ICU in Palestine; it is not evident if these cases are attributed to SARS-CoV-2 or coincidental as there is little available data. Finally, antimicrobial stewardship, appropriate patient assessment, and selecting the appropriate antimicrobial agents for the right patient at the right time will decrease hospital stay, mortality, and health care costs.

Data availability

Underlying data

DRYAD: Raw data and SPSS analysis for the article Bacterial and fungal co-infections among ICU COVID-19 hospitalized patients in a Palestinian hospital: Incidence and antimicrobial stewardship. https://doi.org/10.5061/dryad.08kprr53r.

This project contains the following underlying data:

- raw_data.xlsx (raw underlying data)

- Readme.docx (data key)

- variabels_and_Output_final.pdf (SPSS output file)

Data are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication).

Author contributions

HN Project Administration, Supervision, Writing – Review & Editing, UM and YS Data Curation, Writing – Original Draft Preparation, Formal Analysis, NA Formal Analysis, Writing – Original Draft Preparation, AA Methodology, Writing – Review & Editing, MD Methodology, Writing – Review & Editing, IA Data Curation, MF Writing – Review & Editing. All authors read and approved the final manuscript.

Acknowledgments

Reference

1. Singhal T: **A Review of Coronavirus Disease-2019 (COVID-19).** *Indian J. Pediatr.* 2020; **87**: 281–286.
   PubMed Abstract | **Publisher Full Text**

2. Miranda C, Silva V, Capita R, *et al.*: **Implications of antibiotics use during the COVID-19 pandemic: Present and future.** *J. Antimicrob. Chemother.* 2020; **75**: 3413–3416.
   Publisher Full Text

3. Hendaus MA, Jomha FA: **Covid-19 induced superimposed bacterial infection.** *J. Biomol. Struct. Dyn.* 2020; **39**: 4185–4191.
   Publisher Full Text

4. Chaplin S: **COVID -19: a brief history and treatments in development.** *Prescriber.* 2020; **31**: 23–28.
   Publisher Full Text

5. Morris DE, Cleary DW, Clarke SC: **Secondary bacterial infections associated with influenza pandemics.** *Front. Microbiol.* 2017; **8**.
   PubMed Abstract | **Publisher Full Text**

6. Huttner BD, Catho G, Pano-Pardo JR, *et al.*: **COVID-19: don't neglect antimicrobial stewardship principles!.** *Clin. Microbiol. Infect.* 2020; **26**(7): 808–810. Elsevier B.V. 2020 Jul

7. Karaba SM, Jones G, Helsel T, *et al.*: **Prevalence of co-infection at the time of hospital admission in COVID-19 patients, a multicenter study**. *InOpen forum infectious diseases.* US: Oxford University Press; 2021 Jan; (Vol. **8**, No. 1, p. ofaa578).

8. Elabbadi A, Turpin M, Gerotziafas GT, *et al.*: **Bacterial coinfection in critically ill COVID-19 patients with severe pneumonia.** *Infection.* 2021 Jun; **49**(3): 559–562.
   PubMed Abstract | **Publisher Full Text**

9. Karami Z, Knoop BT, Dofferhoff ASM, *et al.*: **Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands.** *Infect. Dis. (Auckl).* 2021; **53**: 102–110.
   Publisher Full Text

10. Prasetyoputri A: **Detection of Bacterial Coinfection in COVID-19 Patients Is a Missing Piece of the Puzzle in the COVID-19 Management in Indonesia.** *ACS Infect. Dis.* 2021; **7**: 203–205.
    PubMed Abstract | **Publisher Full Text**

11. Peng J, Wang Q, Mei H, *et al.*: **Fungal co-infection in COVID-19 patients: evidence from a systematic review and meta-analysis.** 2021; **13**: 7745–7757.

12. Prasso JE, Deng JC: **Postviral Complications: Bacterial Pneumonia.** *Clin. Chest. Med.* 2017; **38**: 127–138.
    PubMed Abstract | **Publisher Full Text**

13. Avadhanula V, Rodriguez CA, DeVincenzo JP, *et al*.: **Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species-and cell type-dependent manner.** *J. Virol.* 2006 Feb 15; **80**(4): 1629–1636.
PubMed Abstract | **Publisher Full Text**

14. Langford BJ, So M, Raybardhan S, *et al*.: **Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis.** *Clin. Microbiol. Infect.* 2020 Jul 22; **26**: 1622–1629.
PubMed Abstract | **Publisher Full Text**

15. Lucien MAB, Canarie MF, Kilgore PE, *et al*.: **Antibiotics and antimicrobial resistance in the COVID-19 era: Perspective from resource-limited settings.** *Int. J. Infect. Dis.* 2021. Elsevier B.V.

16. Sieswerda E, de Boer MGJ, Bonten MMJ, *et al*.: **Recommendations for antibacterial therapy in adults with COVID-19 – an evidence based guideline.** *Clin. Microbiol. Infect.* 2021; **27**: 61–66.
PubMed Abstract | **Publisher Full Text**

17. Liu C, Wen Y, Wan W, *et al*.: **Clinical characteristics and antibiotics treatment in suspected bacterial infection patients with COVID-19.** *Int. Immunopharmacol.* 2021; **90**: 107157.
Publisher Full Text

18. Pulia MS, Wolf I, Schulz LT, *et al*.: **COVID-19: An emerging threat to antibiotic stewardship in the emergency department.** *West J. Emerg. Med.* 2020; **21**: 1283–1286.
PubMed Abstract | **Publisher Full Text**

19. Abelenda-Alonso G, Padullés A, Rombauts A, *et al*.: **Antibiotic prescription during the COVID-19 pandemic: A biphasic pattern.** *Infect. Control Hosp. Epidemiol.* 2020; **41**: 1371–1372.
PubMed Abstract | **Publisher Full Text**

20. Quah P, Li A, Phua J, Phua J: **Mortality rates of patients with COVID-19 in the intensive care unit: A systematic review of the emerging literature.** *Crit. Care.* 2020; **24**: 285. BioMed Central Ltd.
PubMed Abstract | **Publisher Full Text**

21. Song G, Liang G, Liu W: **Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China.** *Mycopathologia.* 2020; **185**: 599–606.
PubMed Abstract | **Publisher Full Text**

22. Du Y, Tu L, Zhu P, *et al*.: **Clinical features of 85 fatal cases of COVID-19 from Wuhan: A retrospective observational study.** *Am. J. Respir. Crit. Care Med.* 2020; **201**: 1372–1379.
PubMed Abstract | **Publisher Full Text**

23. Yang X, Yu Y, Xu J, *et al*.: **Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.** *Lancet Respir. Med.* 2020; **8**: 475–481.
PubMed Abstract | **Publisher Full Text**

24. Frater JL, Zini G, d'Onofrio G, *et al*.: **COVID-19 and the clinical hematology laboratory.** *Int. J. Lab. Hematol.* 2020; **42**: 11–18.
PubMed Abstract | **Publisher Full Text**

25. Yamada T, Wakabayashi M, Yamaji T, *et al*.: **Value of leukocytosis and elevated C-reactive protein in predicting severe coronavirus 2019 (COVID-19): A systematic review and meta-analysis.** *Clin. Chim. Acta.* 2020; **509**: 235–243.
PubMed Abstract | **Publisher Full Text**

26. Greenhalgh T, Knight M, Inda-Kim M, *et al*.: **Remote management of covid-19 using home pulse oximetry and virtual ward support.** *BMJ.* 2021; **372**.
Publisher Full Text

27. Pourbagheri-Sigaroodi A, Bashash D, Fateh F, *et al*.: **Laboratory findings in COVID-19 diagnosis and prognosis.** *Clinica Chimica Acta; International Journal of Clinical Chemistry.* 2020 Nov; **510**: 475–482.
PubMed Abstract | **Publisher Full Text**

28. Yamada T, Wakabayashi M, Yamaji T, *et al*.: **Value of leukocytosis and elevated C-reactive protein in predicting severe coronavirus 2019 (COVID-19): a systematic review and meta-analysis.** *Clin. Chim. Acta.* 2020 Oct 1; **509**: 235–243.
PubMed Abstract | **Publisher Full Text**

29. Reddy RK, Charles WN, Sklavounos A, *et al*.: **The effect of smoking on COVID-19 severity: A systematic review and meta-analysis.** *J. Med. Virol.* 2021; **93**: 1045–1056.
PubMed Abstract | **Publisher Full Text**

30. Leung JM, Leung JM, Yang CX, *et al*.: **Current smoking is not associated with COVID-19.** *Eur. Respir. J.* 2020; **55**: 2001340–2001310.
PubMed Abstract | **Publisher Full Text**

31. Zhang H, Wang X, Fu Z, *et al*.: **Potential Factors for Prediction of Disease Severity of COVID-19 Patients.** 2020.
Publisher Full Text

32. Gómez-Belda AB, Fernández-Garcés M, Mateo-Sanchis E, *et al*.: **COVID-19 in older adults: What are the differences with younger patients?.** *Geriatr. Gerontol. Int.* 2021; **21**: 60–65.
PubMed Abstract | **Publisher Full Text**

33. Agrawal H, Das N, Nathani S, *et al*.: **An Assessment on Impact of COVID-19 Infection in a Gender Specific Manner.** *Stem Cell Rev. Rep.* 2021; **17**: 94–112.
PubMed Abstract | **Publisher Full Text**

34. Biswas M, Rahaman S, Biswas TK, *et al*.: **Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis.** *Intervirology.* 2021; **64**: 36–47.
PubMed Abstract | **Publisher Full Text**

35. Qiu P, Zhou Y, Wang F, *et al*.: **Clinical characteristics, laboratory outcome characteristics, comorbidities, and complications of related COVID-19 deceased: a systematic review and meta-analysis.** *Aging Clin. Exp. Res.* 2020; **32**: 1869–1878.
PubMed Abstract | **Publisher Full Text**

36. Baron DM, Franchini M, Goobie SM, *et al*.: **Patient blood management during the COVID–19 pandemic: a narrative review.** *Anaesthesia.* 2020; **75**: 1105–1113.
PubMed Abstract | **Publisher Full Text**

37. Taneri PE, Gómez-Ochoa SA, Llanaj E, *et al*.: **Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis.** *Eur. J. Epidemiol.* 2020; **35**: 763–773.
PubMed Abstract | **Publisher Full Text**

38. De Flora S, Balansky R, La Maestra S: **Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19.** *FASEB J.* 2020; **34**: 13185–13193.
PubMed Abstract | **Publisher Full Text**

Open Peer Review

Current Peer Review Status: ✓ ✓

- -

Version 2

Reviewer Report 17 June 2022

https://doi.org/10.5256/f1000research.134315.r139417

✓ **Hamza Maswade**

College of Pharmacy, Qassim University, Buraydah, Saudi Arabia

All changes are made to the manuscript, no additional comments. I believe that the revised version is acceptable.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 01 June 2022

https://doi.org/10.5256/f1000research.134315.r139416

✓ **Maher Khdour** [iD]

Faculty of Pharmacy, Al-Quds University, Abu Dis, Palestinian Territory

Bacterial and fungal co-infections among ICU COVID-19 hospitalized patients in a Palestinian hospital: a retrospective cross-sectional study - version 2

The authors have substantially addressed all questions raised during the review process for the manuscript.
I can assure readers that the study adds value to the health policy maker and international literature.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: clinical pharmacy, pharmacy practice, pharmaceutical care, medications, drug utilization, disease management.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 16 May 2022

https://doi.org/10.5256/f1000research.78339.r130200

? **Hamza Maswade**
College of Pharmacy, Qassim University, Buraydah, Saudi Arabia

The manuscript entitled "Bacterial and fungal co-infections among ICU COVID-19 hospitalized patients in a Palestinian hospital: a retrospective cross-sectional study" is a study to investigate the burden of bacterial and fungal co-infections outcomes on COVID-19 patients. It is a single center cross-sectional study of hospitalized COVID-19 patients at Beit-Jala hospital in Palestine. The study is important and well written; however there are some comments, such as:

- Please, add the duration of ICU stay (day) chronic cross tabulation.

- Please, if it's possible, classify patients according to the number of chronic diseases for each patient.

- Table 1 the author(s) provide the percent for:

  Diabetes mellitus 250 (77.9%)
  Atrial hypertension 213 (66.4%)
  Obesity 118 (36.8%)
  Coronary heart disease 74 (23.1%)
  Cancer

However; in table 2 "Impact of different non-significant values on the duration in the ICU", they did not mention the data for coronary heart disease and for cancer. Please add the data in table 2 and make a discussion for the results concerning patients with coronary heart disease and cancer.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

> Author Response 21 May 2022
>
> **Hani Naseef**, Birzeit University, Ramallah, Palestinian Territory
>
> Dear Dr. Hamza, Thank you for your valuable comments. Following are our responses point-by-point to your comments:
>
> 1- Comment 1: Done.
>
> 2- Comment 2: Done, added to table 2.
>
> 3- Comment 3: Done "A significant association was found between the residency duration and having a personal history with no chronic diseases (P= 0.035): (3; 23.1%) of patients with no chronic diseases have died after being admitted to ICU compared to (23; 7.5%) of patients diagnosed with at least one chronic disease."
>
> *Competing Interests:* No

Reviewer Report 01 February 2022

https://doi.org/10.5256/f1000research.78339.r119466

? **Maher Khdour** iD

Faculty of Pharmacy, Al-Quds University, Abu Dis, Palestinian Territory

Bacterial and fungal co-infections among ICU COVID-19 hospitalized patients in a Palestinian hospital: a retrospective cross-sectional study

The paper and subject are both valuable and are important to the scientific community, especially in this situation during the pandemic Covid-19. The paper is well-written, however some issues were raised during the review process and should be addressed:

○ In the abstract it is not clear whether the patients get infected at admission or during their stay in the ICU.

○ All results data e.g. "The rate of bacterial co-infection was 51.1%..." should include infected patients / total patients and for mortality rate please state the CI.

○ Abstract conclusion (see if it fit the journal regulations as I see it long?).

○ Study design should be clearer to readers.

○ 458 records screened and 321 positive (this will result in 70% infected); if this is the case, please add the over all co-infection in the sample of 70% to your results.

○ Between 4.5-8.5 mg/dL was rated as moderate and ≥8.5 mg/dL was rated as severe. Leukocyte results in the 4.6-8 g/L range were considered mild, while >8 g/L indicated seriously ill patients: this is not mentioned in your results or in the abstract and you can find a good correlation between the severity and co-infection, I think this will make the abstract much better.

○ How did you calculate the mortality rate (should be stated in the method section, all causes)?

○ Some significant data in tables 2 and 3 worth mentioning in the results of abstract with P values.

○ Under the tables, please state the test you used (Chi square) and be sure the abbreviations match too.

○ In the discussion (mortality rate 8.1 vs 25% in other developed countries) do you think there is under-reporting or documentation of co-infection in Palestinian hospitals, or is this due to the broad antibiotic used which is restricted in other countries due to resistance concerns?

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: clinical pharmacy, pharmacy practice, pharmaceutical care, medications, drug utilization, disease management.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 03 Feb 2022

Hani Naseef, Birzeit University, Ramallah, Palestinian Territory

Dear Dr. Maher
Thank you for your valuable comments, when the article has received a second peer review report I will submit a revised version 2 of the article incorporating the changes as you requested.

Competing Interests: No competing interests were disclosed.

Author Response 21 May 2022

Hani Naseef, Birzeit University, Ramallah, Palestinian Territory

Dear Dr. Maher Thank you for your valuable comments. Following are our responses point-by-point to your comments:

1- comment 1: Clarified "with a confirmed diagnosis of COVID-19 via reverse transcriptase-polymerase chain reaction assay conducted on a nasopharyngeal swab and has a positive culture for bacteria or fungi as upon hospital admission".

2- comment 2: Done in all the text.

3- comment 3: As per the Article Guidelines: the abstract should be up to 300 words long, The abstract of the manuscript fits the journal's instructions.

4- comment 4: Changed and clarified the text.

5- comment 5: Clarified " A total of 458 records of moderate-severe COVID-19 ill patients were screened and evaluated. Of those, 321 patients with positive cultures for bacteria or fungi were included in the study, and patients with negative cultures were excluded".

6- comment 6: This is already done and written in Table 2, but due to the absence of the association, as the chi-square result revealed, we did not mention it either in the text or in the abstract.

7- comment 7: Rewritten: "The overall mortality rate for our sample in this study was (26/321*100%= 8.1%)".

8- comment 8: Done " A significant association was found between the residency duration and SpO 2 (P=0.032). The results revealed a significant association between ICU residency duration and the empirical antibiotics (P<0.001)."

9- comment 9: Done for tables 2 and 3.

10- comment 10: Done "The mortality rate of 8.1% (26) for patients admitted to the ICU due to Covid-19 coinfections found by this study is much lower than other reported rates of 25.7 % in a systematic review that included 15 studies in different countries. Despite the absence of antimicrobial stewardship in urgent response, the hospital's initiation of drastic empirical administration was crucial for preventing or treating suspected infections. In addition, the hospital's guideline adherence to empiric antimicrobial therapy and the other drugs was adequate. Furthermore, many factors could affect this finding, including the age and living situations; in our sample, two-thirds of participants were less than 65 years old. In addition, all participants did not live in nursing homes or elderly homes where a higher rate of antimicrobial resistance is expected."

Competing Interests: No

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias

- You can publish traditional articles, null/negative results, case reports, data notes and more

- The peer review process is transparent and collaborative

- Your article is indexed in PubMed after passing peer review

- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research